TASIGNA
Total Payments
$39.5M
Transactions
27,101
Doctors
6,472
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $307,799 | 38 | 23 |
| 2023 | $547,658 | 2,789 | 1,932 |
| 2022 | $479,382 | 1,372 | 866 |
| 2021 | $512,705 | 1,962 | 1,231 |
| 2020 | $885,794 | 663 | 451 |
| 2019 | $4.4M | 2,885 | 1,355 |
| 2018 | $9.7M | 7,908 | 2,679 |
| 2017 | $22.7M | 9,484 | 3,196 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $37.8M | 543 | 95.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $521,198 | 173 | 1.3% |
| Consulting Fee | $493,398 | 138 | 1.2% |
| Food and Beverage | $453,001 | 25,759 | 1.1% |
| Space rental or facility fees (teaching hospital only) | $148,404 | 118 | 0.4% |
| Travel and Lodging | $138,634 | 358 | 0.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,965 | 1 | 0.0% |
| Education | $28.42 | 11 | 0.0% |
Payments by Type
Research
$37.8M
543 transactions
General
$1.8M
26,558 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE III MULTI CENTER OPEN LABEL RANDOMIZED STUDY OF IMATINIB VERSUS NILOTINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE PH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE CML CP | Novartis Pharmaceuticals Corporation | $11.1M | 1 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE IIA PARALLEL GROUP TWO COHORT STUDY TO DEFINE THE SAFETY TOLERABILITY CLINICAL AND EXPLORATORY BIOLOGICAL ACTIVITY OF THE CHRONIC ADMINISTRATION OF NILOTINIB IN PARTICIPANTS WITH PARKINSONS DISEASE PD | Novartis Pharmaceuticals Corporation | $7.4M | 0 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE IMPACT OF LOW DOSES OF NILOTINIB TREATMENT ON SAFETY TOLERABILITY PHARMACOKINETICS AND BIOMARKERS IN PARKINSONS DISEASE | Novartis Pharmaceuticals Corporation | $5.1M | 0 |
| A MULTI CENTER OPEN LABEL NON CONTROLLED PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL NILOTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PH CHRONIC MYELOGENOUS LEUKEMIA CML IN CHRONIC PHASE CP OR WITH PH CML IN CP OR ACCELERATED PHASE AP RESISTANT OR INTOLERANT TO EITHER IMATINIB OR DASATINIB | Novartis Pharmaceuticals Corporation | $3.5M | 0 |
| PHASE II STUDY OF MMR RATES FOLLOWING NILOTINIB DISCONTINUATION AFTER ACHIEVING AND MAINTAINING MR FOUR AND A HALF FOR 1 VERSUS 2 YEARS | Novartis Pharmaceuticals Corporation | $2.9M | 0 |
| DETECTION MONITORING AND MOLECULAR CHARACTERIZATION OF LEUKEMIC STEM CELLS FROM PATIENTS WITH CHRONIC MYELOID LEUKEMIA CML UNDERGOING THERAPY WITH NILOTINIB | Novartis Pharmaceuticals Corporation | $2.0M | 0 |
| A PHASE II SINGLE ARM OPEN LABEL STUDY OF NILOTINIB DISCONTINUATION AFTER ACHIEVING AND MAINTAINING MR FOUR AND A HALF | Novartis Pharmaceuticals Corporation | $1.4M | 0 |
| A MULTI CENTER OPEN LABEL NON CONTROLLED PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF ORAL NILOTINIB IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PH CHRONIC MYELOGENOUS LEUKEMIA CML IN CHRONIC PHASE CP OR WITH PH CML IN CP OR ACCELERATED PHASE AP RESIS | Novartis Pharmaceuticals Corporation | $1.1M | 0 |
| A SINGLE ARM MULTICENTER NILOTINIB TREATMENT FREE REMISSION STUDY IN PATIENTS WITH BCR ABL1 POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE WHO HAVE ACHIEVED DURABLE MINIMAL RESIDUAL DISEASE MRD STATUS ON FIRST LINE NILOTINIB TREATMENT | Novartis Pharmaceuticals Corporation | $826,903 | 0 |
| AN OPEN LABEL MULTI CENTER NILOTINIB ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTISSPONSORED NILOTINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED NILOTINIB TREATMENT | Novartis Pharmaceuticals Corporation | $538,440 | 0 |
| PHASE I DOSE ESCALATION STUDY TO DETERMINE THE MTD AND DLTS OF PREOPERATIVE OR DEFINITIVE ADMINISTRATION OF NILOTINIB GIVEN CONCURRENTLY WITH RADIATION FOR PATIENTS WITH RECURRENT OR UNRESECTABLE CHORDOMA | Novartis Pharmaceuticals Corporation | $439,222 | 0 |
| A phase II single arm open label study of nilotinib discontinuation after achieving and maintaining MR four and a half | Novartis Pharmaceuticals Corporation | $420,365 | 0 |
| COMBINATION NILOTINIB AND CHEMOTHERAPY AS A FRONT LINE THERAPY FOR PATIENTS WITH KIT MUTATED OR OVEREXPRESSED AML | Novartis Pharmaceuticals Corporation | $279,576 | 0 |
| A single arm multicenter nilotinib treatment free remission study in patients with BCR ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease MRD status on first line nilotinib treatment | Novartis Pharmaceuticals Corporation | $161,228 | 0 |
| A PHASE I AND OR II STUDY OF PDGFR KINASE INHIBITOR IN BIOMARKER ENRICHED RECURRENT MALIGNANT GLIOMAS | Novartis Pharmaceuticals Corporation | $100,924 | 0 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $89,920 | 22 |
| A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension | Novartis Pharmaceuticals Corporation | $81,136 | 0 |
| Phase I dose escalation study to determine the MTD and DLTs of preoperative or definitive administration of nilotinib given concurrently with radiation for patients with recurrent or unresectable chordoma | Novartis Pharmaceuticals Corporation | $55,330 | 0 |
| A PHASE I II STUDY OF RUXOLITINIB IN COMBINATION WITH NILOTINIB IN PATIENTS WITH CHRONIC PHASE CML WHO HAVE ACHIEVED A COMPLETE HEMATOLOGIC REMISSION COMPLETE CYTOGENETIC REMISSION AND MAJOR MOLECULAR REMISSION BUT NOT A COMPLETE MOLECULAR REMISSION ON A TYROSINE KINASE INHIBITOR ALONE | Novartis Pharmaceuticals Corporation | $50,611 | 0 |
| An open label multi center nilotinib rollover protocol for patients who have completed a previous Novartissponsored nilotinib study and are judged by the investigator to benefit from continued nilotinib treatment | Novartis Pharmaceuticals Corporation | $47,048 | 0 |
Top Doctors Receiving Payments for TASIGNA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Allentown, PA | $37.8M | 549 |
| , MD | Internal Medicine | Ann Arbor, MI | $103,824 | 74 |
| , M.D | Internal Medicine | Louisville, KY | $70,868 | 74 |
| , M.D | Hematology | Hawthorne, NY | $63,072 | 56 |
| , MD | Hematology | New York, NY | $57,409 | 20 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $43,961 | 33 |
| , MD | Internal Medicine | Royal Oak, MI | $35,022 | 21 |
| , M.D | Hematology & Oncology | Los Angeles, CA | $33,597 | 30 |
| , MD | Medical Oncology | Seattle, WA | $33,593 | 37 |
| , MD | Hematology & Oncology | Milwaukee, WI | $28,935 | 26 |
| , MD | Internal Medicine | New York, NY | $26,088 | 19 |
| , M.D., PH.D | Hematology & Oncology | Louisville, KY | $25,690 | 26 |
| , MD | Hematology & Oncology | Orlando, FL | $22,912 | 15 |
| , MD | Internal Medicine | Tampa, FL | $22,551 | 17 |
| , MD | Hematology & Oncology | Miami, FL | $21,939 | 47 |
| , MD | Medical Oncology | Baltimore, MD | $21,067 | 24 |
| , M.D | Hematology & Oncology | Henderson, NV | $20,535 | 40 |
| , MD | Hematology & Oncology | Cleveland, OH | $20,380 | 24 |
| , MD | Hematology | Fresno, CA | $19,846 | 13 |
| , M.D | Hematology | Indianapolis, IN | $19,119 | 11 |
| , M.D | Internal Medicine | Denver, CO | $18,509 | 25 |
| , M.D | Hematology | Hackensack, NJ | $18,225 | 23 |
| , MD | Hematology & Oncology | Hackensack, NJ | $17,800 | 13 |
| , MD | Internal Medicine | Morgantown, WV | $17,670 | 17 |
| , M.D | Hematology & Oncology | Sacramento, CA | $16,658 | 14 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $39.5M
- Total Doctors 6,472
- Transactions 27,101
About TASIGNA
TASIGNA is a drug associated with $39.5M in payments to 6,472 healthcare providers, recorded across 27,101 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $307,799 was paid across 38 transactions to 23 doctors.
The most common payment nature for TASIGNA is "Unspecified" ($37.8M, 95.6% of total).
TASIGNA is associated with 20 research studies, including "A PHASE III MULTI CENTER OPEN LABEL RANDOMIZED STUDY OF IMATINIB VERSUS NILOTINIB IN ADULT PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE PH CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE CML CP" ($11.1M).